Do Opioids Actually Work for Back Pain? The Lancet OPAL Answer

Why This Question Matters

"The question was never whether the pain is real. It is whether the opioid does anything the sugar pill does not."

Acute low back and neck pain send an enormous number of people through primary care and emergency rooms every year. For a long time, a short opioid script was a normal part of that visit, built on a reasonable-sounding assumption: strong pain calls for a strong painkiller. The trouble is that assumption was never tested cleanly against a placebo in this exact setting, so nobody actually knew whether the opioid earned its place or just rode along with the natural recovery that most acute back pain follows anyway.

That gap matters because opioids are not a free lunch. They carry a known risk of dependence and misuse, even after a short course, and the human cost of getting that trade-off wrong is severe. So the practical question is not academic. If the drug does not clearly beat a placebo for this kind of pain, then the risk sits on one side of the scale with very little on the other. The OPAL trial was built to weigh exactly that.

How the OPAL Trial Was Built

The Lancet published OPAL, short for Opioid Analgesia for acute Low back and neck pain, in 2023 (Jones and colleagues, 2023). The team recruited 347 adults presenting to one of 157 primary care practices or emergency departments in Sydney, Australia, with recent low back pain, neck pain, or both, of at least moderate severity. Everyone received the same guideline-recommended care, which is reassurance, advice to stay active, and simple analgesia. On top of that, participants were randomly assigned to add either an opioid, oxycodone with naloxone at up to 20 milligrams of oxycodone per day, or a placebo made to look identical, for up to 6 weeks.

"Triple-blind means no one in the room knew who got the drug, which is exactly how you keep hope and expectation from masquerading as relief."

The design is what gives this study its weight. It was triple-blind, meaning the patients, the treating clinicians, and the outcome assessors were all kept unaware of who received the real opioid. That blinding is not a technicality. Pain is heavily shaped by expectation, and a placebo can produce genuine relief on its own. The only way to see whether an opioid does anything beyond that expectation effect is to compare it against an identical-looking placebo with everyone blinded. The primary question was simple: how much pain, on a 0 to 10 scale, would each group report at 6 weeks?

What Did OPAL Find at Six Weeks?

At the 6-week mark, the mean pain score was 2.78 out of 10 in the opioid group and 2.25 in the placebo group (Jones and colleagues, 2023). The adjusted difference of 0.53 points not only failed to favor the opioid, it tilted slightly the other way, toward placebo, and it did not reach statistical significance (95% CI -0.00 to 1.07, p=0.051). In plain terms, the group taking a real opioid did not feel better than the group taking a dummy pill. Both improved, because most acute back and neck pain improves with time and sensible care, but the drug added nothing detectable to that recovery.

"A real opioid did not out-relieve a pill with no medicine in it. That single sentence should reset how we treat a hurting back."

The absence of benefit ran across every outcome the researchers checked, not just pain. Physical function, quality of life, and time to recovery all came out the same in both groups. When a powerful drug shows no edge over placebo on a single well-run trial of this size, that is a strong signal. When it shows no edge on every outcome measured, the signal is hard to argue with.

What Happened at One Year?

A trial that only reported the 6-week tie would already argue against opioids here, because a drug with real risks and no proven benefit is a bad trade. OPAL went further and followed participants out to 52 weeks. At one year, the opioid group did not just fail to pull ahead. They reported slightly worse pain than the placebo group (Jones and colleagues, 2023).

The safety signal is the part I want patients to sit with. At 52 weeks, 24 of 123 people in the opioid group, about 20 percent, screened positive for risk of opioid misuse on the Current Opioid Misuse Measure, a standard validated questionnaire. In the placebo group it was 13 of 128, about 10 percent. That is double the misuse risk, traced back to a short, guideline-style course of medication for ordinary acute pain. The authors concluded plainly that opioids should not be recommended for acute non-specific low back or neck pain.

"A few weeks of pills for a sore back doubled the one-year misuse risk and bought no relief. That is the whole trade laid bare."

This is also where the OPAL result connects to the wider record on conservative care. In a separate Forward Review analysis of insurance-claims data, patients who saw a chiropractor for spine pain filled markedly fewer opioid prescriptions than those who did not, a pattern covered in the companion piece on chiropractic care and opioid reduction for spine pain. OPAL explains the mechanism behind that pattern from the other direction: when the drug adds nothing, a care path that leans on movement and hands-on treatment has room to lower opioid exposure without giving up relief.

Does This Mean Opioids Are Useless for Every Kind of Pain?

It would be a mistake to read OPAL as a blanket verdict on opioids. These drugs have a real and humane role in acute severe pain from surgery, major trauma, and cancer, where the calculus is different and the alternatives are limited. Overreacting to a study by swinging to the opposite extreme is its own error, and it can leave people with genuine severe pain undertreated.

What OPAL narrows in on is one very common scenario: acute, non-specific low back and neck pain, the mechanical kind that most adults will feel at some point. In that specific setting, and against the strongest comparison available, the opioid did not deliver. The earlier evidence base pointed the same direction. A Cochrane systematic review of 15 trials and more than 5,000 patients found that opioids gave only modest short-term relief for chronic low back pain, with trials too short to judge long-term benefit, tolerance, or addiction (Chaparro and colleagues, 2013). OPAL added the missing acute-pain, placebo-controlled piece and found the benefit was not modest, it was absent.

What Do the Guidelines Say Now?

OPAL did not arrive in a vacuum. The major guideline bodies had already been steering away from opioids for back pain, and this trial hardened the case. The American College of Physicians, in its clinical practice guideline for low back pain, recommends that clinicians and patients start with non-drug options: superficial heat, massage, acupuncture, and spinal manipulation for acute pain, and exercise and rehabilitation approaches for chronic pain. Opioids appear only as a last option, to be considered when other treatments have failed and only after an honest conversation about the known risks against realistic benefits (Qaseem and colleagues, 2017).

The pattern holds internationally. The UK's National Institute for Health and Care Excellence advises against routine opioid use for low back pain and does not recommend opioids for chronic sciatica, reserving weak opioids for acute back pain only when an anti-inflammatory cannot be used (NICE, 2016, updated 2020). When independent guideline panels on two continents reach the same conclusion, and a placebo-controlled trial then confirms it, the direction of care is clear.

What This Means Clinically

I treat people in Tulsa every week who come in with a back that seized up over the weekend or a neck that locked after a rough night of sleep. Years ago, a fair number of them would have left an urgent care with a few days of opioids. What OPAL tells me, and what I already see in the room, is that the drug was rarely the thing that helped. Time and motion helped. The pill mostly came along for the ride and, for a minority, left a problem behind.

"My goal is to lower the cost of the next movement, not to chase the pain with a stronger chemical."

Here is the mechanical picture. When a spinal segment restricts, the muscles around it guard, movement becomes painful, and a person naturally moves less. Moving less stiffens the joint further and the loop tightens. A targeted adjustment with hands-on soft-tissue work can release that restriction enough to make the next movements tolerable, which is what lets the body's normal recovery take over. I am not claiming an adjustment cures anything or works for everyone. I am saying it addresses the mechanical restriction directly, which is a better match for a mechanical problem than a systemic sedating drug that, in this trial, did nothing measurable. For people whose main issue is a hurting low back, I lay out the full conservative approach on the back pain chiropractor in Tulsa resource.

For Recurring Mechanical Pain, Plan for It

When a back or neck problem is a recurring mechanical pattern rather than a one-time flare, I am honest about the time course. These problems tend to compound with each flare. For a pattern that keeps returning, the responsible approach is ongoing care, roughly once a week for at least twelve weeks after the acute phase settles, then tapering based on whether the symptoms return. That is not a contract and not a package sold up front. It is $40 a visit, you stop whenever you want, and the whole aim is to keep you moving on your own rather than dependent on any treatment, mine included.

Patient Translation: What to Do With a Badly Hurting Back

If your back or neck just went out, the evidence-based playbook is calmer than it feels in the moment. Keep moving within tolerance rather than going to bed, because prolonged rest stiffens joints and weakens the muscles that support your spine. Gentle walking, heat, and a simple anti-inflammatory if it is safe for you are reasonable first steps. Most acute episodes settle over days to a few weeks on their own. Hands-on care can shorten the miserable early stretch by getting you moving comfortably sooner, which is exactly where most people get stuck.

The point is not that you should refuse every medication or tough it out in silence. The point is that for this kind of pain, the strongest evidence says an opioid is unlikely to add relief and may add risk. So if you are handed a script for ordinary mechanical back pain, it is completely reasonable to ask whether a non-drug path fits your situation first. That is a normal, informed conversation to have with any clinician, and most will welcome it.